Fecal Calprotectin Test Market Synopsis:
\nFecal Calprotectin Test Market Size Was Valued at USD 122.8 Million in 2023, and is Projected to Reach USD 277.9 Million by 2032, Growing at a CAGR of 12.98% From 2024-2032.
\nThe fecal calprotectin test market is a highly relevant market within the diagnostic space in healthcare, which aims at identifying inflammation in the GI tract. Calprotectin is a white blood cell protein; thus, its elevation in the stool results from intestinal inflammation. There is no cure for this condition but this test is helpful in diagnosis and management of IBD such as Crohn\u2019s disease and ulcerative colitis. Thus, effectively, utilizing calprotectin testing helps distinquish betwen IBD and other GI, which therefore makes much fewer patients require colonoscopies.
\nFecal calprotectin has been on the increase over the years because of high incidence of gastrointestinal diseases and because it is an effective noninvasive diagnostic tool. The market is fuelled by lucrative features of fecal calprotectin tests such as high reactivity, non-interference with bowel movement, and assessment of disease activity or inactivity. Further, more development has seen these test to be more efficient, more accurate and are more available to the population. Therefore, fecal calprotectin testing has now become routine in managing IBD and promoting market progress.
\nLocation wise, the fecal calprotectin test market is growing; the largest markets are the North American and European market because of the more cases of IBD and better healthcare system infrastructure. Though there is still limited, but with the advancement of medical accessibility in emerging economies it has been increasingly used in Asia-Pacific region. This research predicts that the market will keep growing steady, primarily due to the advanced studies in biomarker testing and preventive medical attention. Furthermore, the growing partnership between diagnostic companies and healthcare organizations to increase the affordability of fecal calprotectin kits are also contributing to increased market growth.<\/p>\n
Fecal Calprotectin Test Market Trend Analysis:
\nIncreasing Demand for Non-Invasive Diagnostic Tests<\/p>\n
This is because the fecal calprotectin test is particularly beneficial for diagnosing diseases due to the non invasive nature of the test. As patients and healthcare providers seek less invasive, less painful, and more convenient ways to diagnose and treat conditions such as colon cancer, fecal calprotectin testing is emerging as an important adjunct in the diagnosis and treatment of IBD. This is especially of great aid in the diagnosis of IBD since majority of the citizens can afford the upper end endoscopy instead of other costly procedures including colonoscopy, consequently enhancing the accessibility and efficiency in the health sector.
\nAdvancements in Point-of-Care Testing<\/p>\n
Another new development in the fecal calprotectin test market is the fast development of the POC testing. The availability of transportable, user-friendly testing devices means the fecal calprotectin tests can be performed at outpatient facilities or at home. The POC solutions carry the plus of expediting the diagnosis exercises to an extent of cutting down waiting time thereby making it more convenient. As more institutions implement such technologies, fecal calprotectin testing is becoming more prevalent and will continue to propel market growth in low-resource laboratories.
\nFecal Calprotectin Test Market Segment Analysis:
\nFecal Calprotectin Test Market Segmented on the basis of Assay Type, Indication, End-User, and Region
\nBy Assay Type, Enzyme Fluroimmunoassay segment is expected to dominate the market during the forecast period<\/p>\n
The fecal calprotectin test market is segmented by assay type into three main categories: EIA (Enzyme Immunoassay), enzyme fluoroimmunoassay and chemiluminescent immunoassay and immune chromatography. ELISA is popular since it is well sensitive and specific when used to determine levels of calprotectin in the fecal samples because it is the most used method in clinical laboratories. Enzyme fluoroimmunoassay, which has better detection efficiency and comparatively shorter time to results, is becoming increasingly popular for use at the site of patient care. The immune-chromatography which is a common format in rapid diagnostic kits is proven to be convenient easy, and cost effective rendering easy testing directly from the hours on site particularly in developing nations. These assay types meet different diagnostic requirements so as to enlarge the spectrum of application and enhance the practicability of fecal calprotectin tests in clinic.
\nBy End-User, Hospitals segment expected to held the largest share <\/p>\n
The fecal calprotectin test is divided by end users in hospitals, diagnostic laboratories, academic and research institutes and others. Hospitals are expected to continue leading the market demand because fecal calprotectin tests are particularly used in diagnosing IBS and other gastrointestinal conditions in hospitals. Equipment also involves in performing of these tests and diagnostic laboratories, in particular, has a significant role in offering the right results at the right time to physicians. Medical academia and research generic applicative subdivisions progress clinical knowledge of fecal calprotectin as a biomarker and the development of diagnostic techniques. More importantly, the \u201cothers\u201d segment includes home care settings where point-of-care testing gaining popularity as it is convenient and easy to use.
\nFecal Calprotectin Test Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
Due to various factors which include well developed health care facilities, higher health expenditure, and emphasis on the diagnosis and treatment of GI diseases such as IBD, North America is expected to lead the fecal calprotectin test market revenues during the forecast period. However, the rising consciousness of people regarding the advantages of non-utilizing invasive diagnostic techniques and the use of portable diagnostic testing known as point-of-care testing also play an important role in developing the market in this region. The high level of development of healthcare services in North America and the consistently high demand for new diagnostic technologies can also promote the development of the Fecal Calprotectin test market.
\nActive Key Players in the Fecal Calprotectin Test Market:<\/p>\n
Rad Laboratories, Inc. (United States)<\/p>\n
EagleBio (United States)<\/p>\n
Svar Life Science (Sweden)<\/p>\n
DRG International, Inc. (United States)<\/p>\n
ALPCO (United States)<\/p>\n
Thermo Fisher Scientific Inc. (United States)<\/p>\n
Alpha Laboratories Ltd. (United Kingdom)<\/p>\n
Meridian Bioscience, Inc. (United States)<\/p>\n
B\u00dcHLMANN (Switzerland)<\/p>\n
DIAZYME LABORATORIES, INC. (United States)<\/p>\n
Abbexa (United Kingdom)<\/p>\n
OPERON, S.A. (Spain)<\/p>\n
DiAgam (France)<\/p>\n
R-Biopharm AG (Germany)<\/p>\n
Biomerica (United States)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
The fecal calprotectin test market is a highly relevant market within the diagnostic space in healthcare, which aims at identifying inflammation in the GI tract. Calprotectin is a white blood cell protein; thus, its elevation in the stool results from intestinal inflammation. There is no cure for this condition but this test is helpful in diagnosis and management of IBD such as Crohn\u2019s disease and ulcerative colitis. Thus, effectively, utilizing calprotectin testing helps distinguish between IBD and other GI, which therefore makes much fewer patients require colonoscopies.<\/p>\n","protected":false},"featured_media":24190,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-26999","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n